|

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

RECRUITINGPhase 1/2Sponsored by First Affiliated Hospital of Fujian Medical University
Actively Recruiting
PhasePhase 1/2
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2025-12-20
Est. completion2026-12-31
Eligibility
Age18 Years – 90 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07363382

Summary

The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer, particularly serving as a complementary tool to PSMA PET for addressing cases with negative or insufficient PSMA expression. It demonstrates substantial value in initial staging (especially in intermediate- and high-risk patients), detecting sites of biochemical recurrence, assessing metastatic lesions (notably in mCRPC), and guiding treatment decisions. 68Ga-G21 and 68Ga-G23 are two novel molecular probes targeting GRPR. This study aims to evaluate their biodistribution and diagnostic performance in prostate cancer and compare them with 68Ga-PSMA-11 PET imaging.

Eligibility

Age: 18 Years – 90 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* confirmed treated or untreated prostate cancer patients;
* signed written consent.

Exclusion Criteria:

* known allergy against PSMA;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions2

CancerProstate Cancer (Adenocarcinoma)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.